Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal Carcinoma

HPV 口咽癌的定量组织形态学风险分类器 (QuHbIC)

• 批准号: 9884742
• 负责人: JAMES LEWIS
• 金额: $ 62.42万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-03-08 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9884742
• 关键词: Adoption; Adult; Aftercare; American Joint Committee on Cancer; Architecture; Biological; Cancer Diagnostics; Categories; Cervical; Cessation of life; Chemotherapy and/or radiation; Chromosome abnormality; Classification; Clinic; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Complex; Computer Assisted; Computer Vision Systems; Computer software; Data; Diagnosis; Diagnostic; Diagnostic tests; Disease; Distant; Distant Metastasis; Dose; Eligibility Determination; Enrollment; Environment; Epithelial; Epithelium; Failure; Foundations; HPV-High Risk; Head Cancer; Health Care Costs; Hematoxylin and Eosin Staining Method; Human Papillomavirus; Image; Indolent; International Union Against Cancer; Left; Malignant Neoplasms; Measurement; Mediating; Modeling; Molecular; Morbidity - disease rate; Morphology; Multivariate Analysis; Mutation; Neck Cancer; Nuclear; Oropharyngeal; Oropharyngeal Squamous Cell Carcinoma; Outcome; Pathology; Patient-Focused Outcomes; Patients; Pattern; Pattern Recognition; Phase; Process; Production; Progressive Disease; Publishing; Radiation Therapy Oncology Group; Randomized; Randomized Clinical Trials; Randomized Controlled Clinical Trials; Recurrence; Recurrent disease; Regimen; Regulatory Pathway; Research Personnel; Resources; Retrospective cohort; Risk; Risk stratification; Shapes; Site; Slide; Smoking; Specimen; Squamous cell carcinoma; Stage Grouping; Stains; Stratification; Surgical Oncology; Surgical Pathology; Surrogate Markers; Survival Rate; System; Testing; Texture; Time; Tissue Stains; Tissues; Training; Treatment Failure; Tumor-Infiltrating Lymphocytes; Universities; Uterus; Validation; Visual; Work; base; behavioral outcome; chemoradiation; cohort; commercialization; common treatment; companion diagnostics; computerized; cost; density; digital imaging; digital pathology; disorder risk; economic need; high risk; improved; improved outcome; industry partner; innovation; malignant oropharynx neoplasm; neoplastic cell; outcome forecast; outcome prediction; overtreatment; patient subsets; pharynx squamous cell carcinoma; power analysis; precision medicine; prognostic; prognostic assays; prospective; prototype; success; tool; treatment choice; treatment response; treatment risk; tumor; tumor behavior

SUMMARY: In 2016, nearly 50,000 adults in the US were diagnosed with oral and pharyngeal squamous cell carcinoma (SCC), and nearly 10,000 died from the disease. Human papillomavirus (HPV) is now recognized as the most common cause of oropharyngeal (OP) SCC in the US. Although concomitant chemo- and radio-therapy is the most common treatment choice in patients with advanced OP-SCC, they have substantial short- and long- term morbidity and result in increased health care costs in patients who are cured of their cancers. These patients live with sometimes disabling morbidity for many years post-treatment. For these reasons, it has been suggested that therapy in lower risk patients might be de-escalated. There is also a higher risk cohort of patients in whom treatment with chemo-radiation may be insufficient, often resulting in distant metastatic failure. As such, these patients may require intensified therapies to improve outcomes. This is an agonizing choice for patients and their doctors, however. While patients do not want to be sickened by morbid treatments, they are obviously concerned about having the best chance at cure. Unfortunately, there currently are no companion diagnostic tools to identify which HPV + OPSCC patients are at (1) low risk of recurrence such that they can be treated safely to high cure rates with de-escalated therapy; (2) higher risk of failure despite aggressive high dose chemoradiation in whom treatment intensification strategies should be studied. Recently, we developed a quantitative histomorphometric based image risk classifier (QuHbIC) that uses computerized measurements of tumor morphology (e.g. nuclear orientation, texture, shape, architecture) from digital images of H&E-stained tumor sections to predict progression in HPV+ OP-SCC patients; the current version of QuHbIC has already been validated in >400 patients and found to be superior to clinical variables in outcome prediction. In this Academic-Industry Partnership we seek to further improve predictive accuracy of QuHbIC by incorporating new classes of image features relating to stromal morphology, density and patterns of tumor infiltrating lymphocytes, and tumor cell multi-nucleation, features now recognized as promising markers of unfavorable prognosis in HPV+ OP-SCC. We also seek to create a pre-commercial QuHbIC companion diagnostic test that is ready for clinical use in risk stratification in p16+ OP-SCC. QuHbIC will be trained on >700 retrospectively identified HPV + OP-SCC whole tissue slide images with associated long term outcome data and then validated on 440 cases from randomized, controlled, multi-institutional RTOG 0129 and 0522 clinical trials. This partnership will leverage long-standing collaborations in (1) computational histomorphometry from the Madabhushi group at Case Western Reserve University, (2) surgical pathology and oncology expertise in HPV+ OPSCC from Vanderbilt University and the Cleveland Clinic and, (3) Inspirata Inc., a cancer diagnostics company that will bring quality management systems and production software standards to establish QuHbIC as an Affordable Precision Medicine (APM) solution for oropharyngeal cancers.

摘要：2016年，美国近5万名成年人被诊断为口腔和咽鳞状细胞